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Abstract
Pertussis is a highly infectious respiratory disease of humans caused by the bacterium Bordetella pertussis. Despite high
vaccination coverage, pertussis has re-emerged globally. Causes for the re-emergence of pertussis include limited duration
of protection conferred by acellular pertussis vaccines (aP) and pathogen adaptation. Pathogen adaptations involve
antigenic divergence with vaccine strains, the emergence of strains which show enhanced in vitro expression of a number of
virulence-associated genes and of strains that do not express pertactin, an important aP component. Clearly, the
identification of more effective B. pertussis vaccine antigens is of utmost importance. To identify novel antigens, we used
proteomics to identify B. pertussis proteins regulated by the master virulence regulatory system BvgAS in vitro. Five
candidates proteins were selected and it was confirmed that they were also expressed in the lungs of naı¨ve mice seven days
after infection. The five proteins were expressed in recombinant form, adjuvanted with alum and used to immunize mice as
stand-alone antigens. Subsequent respiratory challenge showed that immunization with the autotransporters Vag8 and
SphB1 significantly reduced bacterial load in the lungs. Whilst these antigens induced strong opsonizing antibody
responses, we found that none of the tested alum-adjuvanted vaccines - including a three-component aP - reduced
bacterial load in the nasopharynx, suggesting that alternative immunological responses may be required for efficient
bacterial clearance from the nasopharynx.
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Introduction
Pertussis (or whooping cough) is a highly contagious, acute
respiratory disease of humans caused by the Gram-negative
bacterium Bordetella pertussis. Although pertussis-related mortal-
ity has dropped significantly after the introduction of childhood
vaccination, pertussis has resurged in many industrialized coun-
tries, with particularly large outbreaks occurring in 2010 and 2012
in Australia, the USA, the UK, the Netherlands, and several other
countries [1–4]. This increase in pertussis incidence is seen mainly
in (vaccinated) adolescents and adults, providing a reservoir for
transmission of pertussis to unvaccinated or partially vaccinated
newborns, who are at greatest risk of developing severe pertussis
[5–7].
Although current pertussis vaccines are effective in limiting the
development of severe clinical symptoms, they are much less
effective in preventing colonization of the upper respiratory tract
and consequently do not adequately reduce circulation in the
population [8]. Moreover, vaccine-induced protection wanes
rapidly leaving vaccinated individuals susceptible to develop
disease after 5–7 years [9]. The apparent inability of current
vaccines to significantly reduce the circulation of B. pertussis may
have facilitated pathogen adaptation. Pathogen adaptation has
resulted in antigenic divergence between vaccine strains and
circulating strains and the emergence of strains, designate P3
strains, which show enhanced in vitro expression of a number of
virulence-associated genes [10,11]. Most recently, strains belong-
ing to the P3 lineage have emerged which do not produce
pertactin (Prn), a component of most aPs. Prn-deficient strains
have reached frequencies of up to 55% in some countries [12–15].
Efforts to improve the immunogenicity of pertussis vaccines have
thus far focused on skewing immunity towards more effective
bacterial clearance, for instance through the use of novel adjuvants
[16,17]. However, the emergence of Prn-deficient strains also
highlights a need to identify novel protective antigens, which may
be included in improved aPs.
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The expression of nearly all pertussis virulence factors, including
the antigens present in aPs, is positively regulated by the two-
component sensory transduction system BvgAS (reviewed in [18]).
Bvg-activated proteins are generally associated with virulence and
modulation or evasion of host immunity [19] and play an
important, or even essential role, during infection. These proteins
therefore represent potential vaccine targets. In vitro, low
temperature and increasing concentration of nicotinic acid or
sulfate are known to suppress the Bvg-system, resulting in the
transition from virulent (Bvg+) through intermediate (Bvgi) to
nonvirulent (Bvg2) bacteria [20]. In this study, we analyzed the
Bvg+, Bvgi, and Bvg2 phase-dependent protein content of two
clinical isolates derived from the P1 and P3 lineages which
dominated globally before and after the 1990s, respectively
[11,21]. Conserved in vivo expressed candidates were then
evaluated for their ability to confer protection against respiratory
infection in mice.
Results
Proteomic analysis and vaccine antigen selection
The regulation of the Bvg-system is dependent on environmen-
tal signals, including free sulfate [20]. In this study, we compared
the proteome of two currently circulating B. pertussis lineages
under in vitro Bvg+ (low sulfate), Bvgi (medium sulfate), and Bvg2
(high sulfate) conditions. B. pertussis strains B1917 and B1920
were used as representatives for the P3 and P1 lineages,
respectively [21]. Bacterial cultures were grown in four replicates
under different Bvg conditions, fractionated into cytosolic and
membrane protein fractions and analyzed by mass spectrometry.
This approach identified a total of 940 proteins in B1917 and 952
proteins in B1920, with 91% overlap between these strains (see
Text S1 and Figure 1A), representing,28% of the predicted 3449
protein-coding ORFs in the B. pertussis genome [22]. The
IDEAL-Q algorithm [23] was used to identify proteins that were
$2.5 fold higher expressed under Bvg+ or Bvgi conditions
compared to the Bvg2 condition, which yielded 159 and 104
Bvg-activated proteins in B1917 and B1920, respectively (Table
S1).
Since P3 and P1 strains both circulate in the population [24],
novel antigens should target both lineages. We therefore first
selected proteins that were Bvg-activated in both strains, resulting
in 51 potential candidates (Figure 1A). Aggregation based on
function and predicted subcellular localization showed that these
51 candidates were significantly enriched for proteins involved in
cellular processes (n = 6, 15%), outer membrane proteins (n = 6,
20%) and extracellular proteins (n = 10, 44%; Figure 1B and C).
Subsequent selection based on Bvg-dependent in vitro transcrip-
tion levels [10], presence in the core genome of B. pertussis [25]
and predicted surface-exposed localization [26] yielded 15 vaccine
candidates (Figure 1A). Of these 15 proteins, eight represent
known B. pertussis protective antigens (Figure 1A), thus validating
our strategy to identify virulence factors, some of which have
proven immunogenic properties. Of the remaining candidates, the
autotransporters SphB1 and Vag8, the TonB-dependent receptor
for iron transport BfrD, the zinc protease BP2497, and the outer
membrane porin protein Q (OmpQ), were selected for further
examination (Figure 1A). Although the outer membrane ligand
binding protein BipA and FhaC are also promising vaccine
candidates based on these criteria, their vaccine potential was not
assessed due to limited resources.
The list of vaccine candidates was supplemented with proteins
that were highly abundant under all Bvg conditions, as these may
also represent attractive targets for the host immune response.
Based on protein abundance estimation by emPAI [27] (Table S2),
the two most abundant proteins, outer membrane proteins A and
P (OmpA, OmpP), were also selected for further analysis.
Recombinant protein production and vaccination
To analyze the protective potential of the selected vaccine
candidates, recombinant His-tagged fusion proteins were ex-
pressed, purified, and refolded. BfrD and OmpQ could not be
produced due to low expression and protein degradation. The five
remaining proteins were adjuvanted with alum (5 mg for each
antigen, 1 mg for SphB1 due to low protein yield) and
administered to BALB/c mice (six mice per group) as stand-alone
antigens by subcutaneous injection at day 0 and 14. In parallel,
groups of mice were vaccinated with a 3-component aP or with
PBS and/or alum. Three weeks after the final vaccination, mice
were challenged by intranasal infection with B. pertussis strain
B1917. B1917 was chosen as the challenge strain, as it belongs to
the predominant P3 lineage, which has spread worldwide [11,24].
Importantly, the amino acid sequences of the tested antigens are
highly conserved in all sequenced B. pertussis strains [24].
aP-vaccinated mice showed the strongest (.220-fold) reduction
in bacterial load in the lungs at both 3 and 7 days after infection.
Of the novel vaccine candidates, rOmpA did not confer any
protection. Although vaccination with rOmpP and rBP2497
resulted in a small but significant reduction of bacterial numbers
in the lungs at day 3 (1.7 and 1.8-fold, respectively), these
differences were not observed at day 7, suggesting that these
proteins have only limited vaccine potential (Figure 2A and B). In
contrast, vaccination with either rSphB1 or rVag8 resulted in a
nearly 10-fold reduction in bacterial load in the lungs at day 3 and
a more pronounced 26 and 68-fold reduction at day 7, respectively
(Figure 2A and B). Of note, although alum-vaccination induced a
significant 7.3-fold reduction in bacterial load in the upper
respiratory tract (URT) at day 7 compared to the PBS group, none
of the vaccines, including aP, was able to reduce bacterial load in
the URT (Figure 2C and D).
Antibody responses to vaccine antigens
To determine the potential role of antibodies in vaccine-
mediated opsonization, ELISA was performed using sera from
vaccinated mice. Figure 3 suggests that all vaccine candidates
induced production of antigen-specific IgG. The absence of pre-
existing antigen-specific antibodies was confirmed using pre-
immune serum. To assess binding to native epitopes on the
bacterial surface, flow cytometry was used to measure binding of
antibodies in serum and nasal lavage to the challenge strain B1917
grown under Bvg+ and Bvg2 conditions. Serum antibodies from
rVag8, rSphB1, and aP-vaccinated mice opsonized Bvg+ bacteria
at significant levels. Although opsonization levels were reduced for
Bvg2 bacteria, rVag8 and aP-vaccinated mice sera still bound
significantly to Bvg2 bacteria (Figure 4A), which is most likely due
to residual expression of these proteins under Bvg2 conditions
(Table S2). For nasal lavage samples, binding to Bvg+ bacteria was
only detected for rVag8 and aP-treated animals (Figure 4B).
Finally, whole-cell ELISA was performed for each antigen.
Analysis of the subtype distribution of opsonizing IgG1, IgG2a,
and IgG2b antibodies showed that IgG1 was the dominant
subtype for each antigen (Figure 4C, D en E).
In vivo expression of vaccine antigens
To determine whether the selected vaccine candidates were
expressed during infection, naı¨ve adult BALB/c mice were
infected intranasally with B1917 or B1920. Seven days after
infection, gene expression was analyzed on bacteria isolated from
Autotransporter-Mediated Protection against B. pertussis
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Figure 1. Vaccine antigen selection and functional clustering of Bvg-activated proteins. A) Putative protein antigens were selected based
on $2.5-fold Bvg-activation at both protein (this work) and mRNA level [10], presence in the core genome of B. pertussis [25], and PSORTb v3.0
predicted surface accessibility (outer membrane or extracellular) [26]. This resulted in the identification of 15 putative vaccine candidates. { known B.
pertussis protective antigens. Proteins in bold were selected for further examination. The proteins in bold The 855 and 51 proteins that were
respectively identified and Bvg-activated at the protein level in both strains, were grouped by functional categories (B) and PSORTb-predicated
subcellular localization (C). The relative frequency of Bvg-activated proteins compared to the total number of annotated proteins identified in both
strains for each functional class are listed on the right-hand side. Asterisks indicate statistically significant enrichment of Bvg-activated proteins in a
certain class as determined by Fisher’s exact test. *p,0.05, ***p,0.0005.
doi:10.1371/journal.pone.0105011.g001
Autotransporter-Mediated Protection against B. pertussis
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the lungs for the five vaccine candidate genes as well as for ptxA,
prn, fhaB, and fim3, which encode all currently used aP antigens
except for Fim2. The expression of these genes was compared to
the kpsT gene, which encodes a protein involved in capsule
biosynthesis that has previously been identified as a Bvg2 gene
[28]. Transcriptional analysis showed that all vaccine candidates
and aP antigens were highly expressed in the lungs of mice in
relation to kpsT (Figure 5).
Discussion
The increase in pertussis outbreaks and the many adaptations
observed in B. pertussis populations, including the down-
regulation of Prn, indicates that more potent pertussis vaccines
are warranted. Here, using an integrated ‘omics’ approach, we
identified OmpP, OmpA, SphB1, Vag8, and BP2497 as in vivo
expressed vaccine candidates. Stand-alone immunization with the
autotransporters SphB1 and Vag8 induced significant protection
against lower respiratory tract (LRT) infection, at a level which
was only 10- and 3-fold lower compared to the reference 3-
component aP vaccine (containing Ptx, Prn, and FHA), respec-
tively. Thus far, four B. pertussis autotransporters have shown to
confer protection in the mouse model, Prn [29], TcfA [30],
SphB1, and Vag8, suggesting that these proteins represent an
attractive class of protective antigens.
Since aluminum adjuvants typically induce a strong T helper
type 2 (Th2) response and high levels of antibodies [31], we
primarily focused on the contribution of antibodies to protection.
Although all five selected vaccine candidates induced significant
levels of specific serum IgGs (predominantly IgG1), only rSphB1
and rVag8 conferred significant protection. A potential explana-
tion for this result may be that only antibodies to rSphB1 and
rVag8 opsonized B. pertussis (Figure 4). The inability of antibodies
specific for rOmpP, rOmpA, and rBP2497 to successfully opsonize
bacteria may be due to incorrect folding of the recombinant
proteins, which is essential to induce bactericidal antibodies
particularly to integral outer membrane proteins like OmpP and
OmpA [32].
At present, the exact mechanisms of protection induced by
SphB1 and Vag8 remain unknown. Antibodies to these proteins
may facilitate phagocytosis and subsequent killing, or result in the
deposition of complement factors on the bacterial surface.
Alternatively, antibodies may neutralize the biological activity of
these antigens. For instance, antibodies against Vag8 may enhance
Figure 2. Effect of immunization with novel vaccine candidates on infection with B. pertussis in the lower and upper respiratory
tract. Naı¨ve adult female BALB/c mice were subcutaneously immunized as described in the text and infected intranasally with 26107 CFU of B.
pertussis strain B1917. The bacterial load in the lungs and nose was quantified three (A&C) and seven (B&D) days after challenge. Each symbol
represents one mouse. Horizontal lines represents the mean. Dashed lines indicate the lower limit of detection. *p,0.05, **p,0.005 relative to PBS
mice; 2-tailed Mann-Whitney U test.
doi:10.1371/journal.pone.0105011.g002
Autotransporter-Mediated Protection against B. pertussis
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the susceptibility of B. pertussis to complement-mediated killing
[33]. Interestingly, SphB1 induced similar protection levels
compared as Vag8 (Figure 2), despite much lower opsonization
levels (Figure 4). This could be a direct consequence of the lower
absolute expression levels of sphB1 during infection compared to
vag8 (Figure 5). Alternatively, the lower level of opsonizing
antibodies may still be sufficient to effectively neutralize the
biological activity of SphB1 on the bacterial surface. SphB1 is a
serine protease which plays an essential role in the maturation of
the adhesin and immune-modulating factor FHA [34]. Previous
studies have shown that deletion of the sphB1 gene dramatically
attenuated the ability of B. pertussis to infect mice [35] and
enhanced phagocytosis [36]. Taken together with our observation
that sphB1 is not expressed at high levels during infection, this
gene represents a very attractive target because even low
concentrations of neutralizing antibodies may be sufficient for
protection.
Although we found that SphB1 and Vag8 were both expressed
during infection in naı¨ve mice, antibodies against these (recom-
binant) antigens were undetectable in convalescent pertussis
patients (data not shown). Although it is possible that these
proteins have poor intrinsic immunogenicity in humans during
natural infection, another explanation may be that vaccinated
individuals who are subsequently infected with B. pertussis
preferentially respond to only a limited number of immunodomi-
nant vaccine antigens, also known as original antigenic sin [37].
Finally, an important observation was that none of the vaccine
formulations, including aP, was able to reduce bacterial coloni-
zation of the URT. As colonization of the URT is probably
essential for transmission, this may explain epidemiological studies
which show that high circulation of B. pertussis occurs despite
widespread aP vaccination [38]. Similarly, recent observations in
the baboon model have shown that aP-vaccinated baboons are
protected against disease but remain susceptible to colonization
and are able to transmit the disease [8]. These data suggest that
the immunological mechanisms which are required for effective
clearance from the lungs (e.g. antibodies [39]) are distinct from
those in the URT, an observation which has also been made for
other respiratory bacterial pathogens, including Streptococcus
pneumonia [40–42]. Cellular immunity in particular may repre-
sent an important component for effective clearance of the URT
[43] and in order to prevent both disease and colonization, a




Animal experiments were approved by the Radboudumc
Committee for Animal Ethics and conducted in accordance with
the relevant Dutch legislation. Bacterial strains were collected by
regional Medical Microbiology Laboratories from patients sus-
pected of whooping cough and sent to the National Institute for
Public Health and the Environment (RIVM) in the context of
routine surveillance (as required by law). The strains are sent to the
RIVM for confirmation of clinical diagnosis, species determination
and subtyping. Strictly anonymized patient information is
included, which is limited to age, sex and postal code. For this
type of surveillance ethical evaluation or patient consent are not
required. The strains have been used in previous studies [48].
Bacterial strains and growth conditions
Culture samples of B. pertussis strains grown under Bvg+, Bvgi,
and Bvg2 conditions in chemically defined THIJS medium [49]
from a previous study [10] were used for proteomic analysis (four
replicates). For modulation of the BvgASR regulatory system,
magnesium sulfate was added to cultures at a final concentration
of 5 and 50 mM to induce Bvgi and Bvg2 conditions respectively.
In the absence of additional sulfate, the concentration of free
sulfate was determined to be 0.02 mM, thereby inducing Bvg+
conditions. Correct modulation of the Bvg system by sulfate was
confirmed in previous work [10]. Bacteria harvested at mid-log
(OD620 of 0.5–0.6) were used for protein isolation.
For recombinant protein expression, Escherichia coli OverEx-
press C41(DE3) (Lucigen, USA) was grown in Luria Bertani
medium (LB) containing appropriate antibiotics (ampicillin,
kanamycin and/or chloramphenicol at a concentration of
50 mg/ml) at 37uC.
Figure 3. Detection of antigen-specific IgG in the serum of immunized mice. Post-immune serum (day 28) was used to determine the
amount of total IgG specific for each recombinant antigens using ELISA as described in the text. Each symbol represents one mouse and the
geometric mean is represented by a line. Dashed lines indicate the lower limit of detection (93 ng/ml). *p,0.05; 1-tailed Wilcoxon Signed Rank Test.
doi:10.1371/journal.pone.0105011.g003
Autotransporter-Mediated Protection against B. pertussis
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Proteomics analysis
Bacterial pellets from 5 ml of mid-log culture were lysed by
sonication. Cytosolic and membrane protein fractions were then
isolated using the ReadyPrep Protein Extraction Kit Membrane I
(Bio-Rad Laboratories, Hercules, CA, USA), according to the
manufacturers protocol. The obtained soluble and insoluble
fractions, containing the cytosolic and membrane (-associated)
proteins respectively, were precipitated using the ReadyPrep 2-D
clean-up Kit (Bio-Rad Laboratories). Protein pellets were then
dissolved in 8 M urea in 10 mM Tris-HCl pH 8.0 and subjected
to in-solution digestion and C18 reversed phase nano flow LC-
MS/MS analysis as described in Text S1.
Recombinant antigen production
The DNA sequences of the selected vaccine antigens lacking
their N-terminal signal sequences and/or other targeting domains
to allow cytosolic expression, were codon optimized for expression
in E. coli, synthesized by GenScript (USA), and cloned into
pET28-TEVsite vector (modified from pET28a vector, Novagen,
Denmark) to generate N-terminally His6-tagged proteins (Table
S3). E. coli OverExpress C41(DE3) (Lucigen, USA) was cultured
to an OD600 = 0.6–0.7 at 37uC, after which recombinant protein
expression was induced through the addition of 1 mM Isopropyl
b-D-1-thiogalactopyranoside (IPTG) for 3 hours. For cell lysis,
bacteria were sonicated in Bacterial Protein Extraction Reagent
(B-PER, Thermo Scientific). Recombinant proteins in inclusion
bodies were dissolved in 20 mM sodium phosphate, 500 mM
NaCl, 4 M urea and 20 mM imidazole and purified on a AKTA
FPLC system using affinity chromatography on a HisTrap FF
crude 1 ml column prepacked with Ni Sepharose 6 Fast Flow (GE
Healthcare, Sweden) as described [50]. Protein concentrations
were determined using the 2-D Quant Kit (GE Healthcare, USA).
Recombinant proteins were refolded by rapid 50-fold dilution in
refolding buffer (for rBP2315 and rBP2497 according to [51] and
for rBP0840 and rBP0943 according to [52]) Refolding of
rBP0216 was performed in 10 mM Benzamidine, 1 mM EDTA,
100 mM NaCL, 1 M urea, and 50 mM diethanolamine (pH9.5).
Vaccination
Individual groups of six naı¨ve female, 6–8 week old BALB/c
mice (Charles River) were immunized subcutaneously on day 0
and 14 with 5 mg of recombinant protein (1 mg for rBP0216 due to
Figure 4. Antibody-mediated opsonization of B. pertussis. The binding of serum (A) and nasal lavage (B) IgG antibodies to Bvg+ or Bvg2
grown B. pertussis B1917 was determined using flow cytometry. Bars represent the geometric mean 695% confidence interval (CI) of 6 individual
mice. *p,0.05, ***p,0.0005 relative to PBS group; Kruskal-Wallis test followed by a Dunns post-hoc test (a=5%). To determine the distribution of IgG
subtypes, whole-cell ELISA was performed with the post-immunization serum samples to detect pertussis-specific IgG1 (C), IgG2a (D), and IgG2b (E).
Each symbol represents one mouse and the geometric mean is represented by a line. Dashed lines indicate the lower limit of detection (23, 4, and
27 ng/ml for IgG1, IgG2a, and IgG2b, respectively). For IgG1, a 1-tailed Wilcoxon Signed Rank Test was performed because IgG1 levels of the PBS mice
were below the detection limit. IgG2a and IgG2b levels were statistically compared to the PBS mice using a 2-tailed Mann-Whitney U-test. *p,0.05,
**p,0.005.
doi:10.1371/journal.pone.0105011.g004
Autotransporter-Mediated Protection against B. pertussis
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low protein yield) mixed 1:1 in 1.3% alum adjuvant (Alhydrogel;
Sigma). As a control, mice were immunized with PBS and
Alhydrogel, or with PBS alone. Since the PBS group was the most
used group for statistical comparisons, 12 mice were included in
this group to enhance the statistical power. In order to compare
efficacy to current aPs, one group of mice was immunized with 1/
50th of the human dose (equals 1.16 mg of B. pertussis protein) of
the commercial hexavalent 3-component acellular pertussis
vaccine Infanrix (GSK, Belgium). On day 35, mice were
challenged by intranasal (i.n.) infection with 26107 colony forming
units (CFU) of B. pertussis strain B1917 in 40 mL. Bacterial load in
the nasopharynx and lungs was determined on day 38 and 42 (3
and 7 days after challenge) as described previously [50]. Including
the 7 day time-point allowed comparison to aP vaccination, which
in mice typically leads to clearance of the pathogen from the lungs
within 7 days [17]. Furthermore, the 3 day time point allowed us
to determine whether the selected antigens are able to induce early
protection against infection. Serum samples were collected on days
0, 28, 38, and 42.
In vivo transcriptional analysis
Groups of 4 female, naı¨ve 6–8 week old BALB/c mice (Charles
River) were infected i.n. with B. pertussis strain B1917 or B1920 as
described above. After 7 days (at the peak of infection), bacteria
were collected from the lungs through a bronchoalveolar lavage
(BAL) with PBS and stabilized with RNA Protect Bacteria
Reagent (Qiagen). Total RNA was extracted using the RNeasy
Mini kit (Qiagen) and contaminating genomic DNA was removed
by DNase treatment (DNAfree, Ambion). Bacterial RNA was
enriched and amplified using the MICROBEnrich (Ambion) and
SensationPlus FFPE Amplification (Affymetrix) kits, respectively.
Enriched RNA was reverse-transcribed using the SuperScript
One-Cycle cDNA Kit (Invitrogen) and used for quantitative real-
time PCR analysis (primer sequences available on request). To
determine relative expression levels, DCt values were calculated by
subtracting the Ct value of the recA (BP2546) household gene from
the Ct value of the target gene [53]. The transcription data are
expressed as 40-DCt value, with 40 representing the number of
PCR cycles as detection limit. A 40-DCt value of 40 indicates that
the gene is expressed at equal levels as recA, while higher values
correspond to increased expression.
Antibody analysis
Protein ELISA. IgG titers against the recombinant antigens
in mouse and human sera were determined by sandwich enzyme-
linked immunosorbent assay (ELISA) analysis, essentially as
described previously [50].
Whole-cell ELISA. The binding of IgG subtypes to whole
bacteria was measured using a whole-cell ELISA method adapted
from Abdillahi and Poolman [54]. Briefly, ELISA plates were
coated with Bvg+ mid-log culture of the challenge strain B1917,
washed with PBS containing 0.05% Tween 20 (PBST), blocked
with 1% BSA/PBS, and incubated with mouse serum. Bound
IgG1, IgG2a, and IgG2b was detected using anti-mouse secondary
antibodies (BD Pharmingin and Southern Biotech) and appropri-
ate substrates. The optical density was measured on an ELISA
plate reader (Tecan Infinite F50) and antibody subtype concen-
trations were determined by comparison to standard curves with
known concentrations of each IgG subtype.
Opsonization. 1% BSA/PBS was used for all dilutions. 106
CFU of Bvg+ and Bvg2 B1917 (challenge strain) were incubated
with serum or nasal lavage (NL) samples from vaccinated mice for
30 min at 4uC. Bacteria were fixed in 2% paraformaldehyde and
surface-bound IgG was detected using anti-mouse IgG-Fc-FITC-
conjugated antibodies (Sigma-Aldrich) on a BD LSRII flow
cytometer (BD Biosciences). The amount of surface-bound
antibodies was expressed in arbitrary units as a fluorescence index
(FI), calculated by multiplying the geometric mean fluorescence
Figure 5. In vivo expression of vaccine-candidate genes. Naı¨ve adult female BALB/c mice (n = 4) were infected intranasally with B. pertussis
strain B1917 or B1920. After 7 days, bacteria were collected through broncho-alveolar lavage and used for in vivo transcriptional analysis using
antigen-specific primers as described in the text. The transcription data is expressed as 40-DCt value, which is a measure of expression relative to the
recA household gene (DCt = Ct target – Ct recA). The number 40 represents the number of PCR cycles. A 40-DCt value of 40 indicates that the gene is
expressed at equal levels as recA, while higher values correspond to higher expression.
doi:10.1371/journal.pone.0105011.g005
Autotransporter-Mediated Protection against B. pertussis
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intensity by the percentage of FITC-positive bacteria [55]. Data
were analyzed using FlowJo version 7.6.5.
Statistical analyses
A 2-tailed Mann-Whitney U test was used for comparison of
bacterial load in NL and lung homogenate between PBS-
vaccinated mice and recombinant antigen-vaccinated mice. A
Kruskal-Wallis test followed by a Dunns post-hoc test (a= 5%) was
used for comparison of antibody-mediated opsonization by serum
and NL samples between PBS-vaccinated mice and recombinant
antigen-vaccinated mice. A 1-tailed Wilcoxon Signed Rank Test
was used to determine whether ELISA measured IgG levels were
significantly above the detection limit. All statistical analyses were
performed using the GraphPad Prism software program, version
5.0, where p,0.05 was considered significant.
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